PDE-5 inhibitor donor intravenous preconditioning is superior to supplementation in standard preservation solution in experimental lung transplantation

European Journal of Cardio-thoracic Surgery

Volumn 32, Issue 1, 2007, Pages 42-47

  Pizanis, Nikolaus ^a   Milekhin, Vitaly ^a   Tsagakis, Konstantinos ^a   Aleksic, Ivan ^a   Kamler, Markus ^a   Jakob, Heinz ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Ischemia reperfusion injury; Lung preservation; Lung transplantation; Phosphodiesterase 5 inhibitor

Indexed keywords

ADRENALIN; FUROSEMIDE; NORADRENALIN; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MODEL; HEMODYNAMICS; ISCHEMIA; LUNG BLOOD VESSEL; LUNG CAPACITY; LUNG EDEMA; LUNG TRANSPLANTATION; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; REPERFUSION INJURY; SUPPLEMENTATION; SWINE; THORACOTOMY; VASCULAR RESISTANCE;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; BLOOD PRESSURE; DRUG EVALUATION, PRECLINICAL; EXTRAVASCULAR LUNG WATER; GRAFT SURVIVAL; LUNG TRANSPLANTATION; MALE; ORGAN PRESERVATION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PULMONARY ARTERY; PULMONARY EDEMA; PURINES; REPERFUSION INJURY; SULFONES; SWINE; TRANSPLANTATION CONDITIONING; VASCULAR RESISTANCE;

EID: 34249873779     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2007.03.044     Document Type: Article

References (18)

1. Muller C., Bittmann I., Hatz R., Kellner B., Schelling G., Furst H., Reichart B., and Schildberg F.W. Improvement of lung preservation - from experiment to clinical practice. Eur Surg Res 34 1-2 (2002) 77-82
2. Burdine J. Heart-lung and lung transplantation: perioperative pulmonary dysfunction. Transplant Proc 23 1 Pt 2 (1991) 1176-1177
3. Herijgers P., Nishimura Y., and Flameng W. Endothelial activation through brain death?. Heart Lung Transplant 23 9 Suppl. (2004) S234-S239
4. Herijgers P., Leunens V., Tjandra-Maga T.B., Mubagwa K., and Flameng W. Changes in organ perfusion after brain death in the rat and its relation to circulating catecholamines. Transplantation 62 3 (1996) 330-335
5. Ghofrani H.A., Wiedemann R., Rose F., Olschewski H., Schermuly R.T., Weissmann N., Seeger W., and Grimminger F. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136 7 (2002) 515-522
6. Ghofrani H.A., Wiedemann R., Rose F., Schermuly R.T., Olschewski H., Weissmann N., Gunther A., Walmrath D., Seeger W., and Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360 9337 (2002) 895-900
7. Hoeper M.M., Spiekerkoetter E., Westerkamp V., Gatzke R., and Fabel H. Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. Eur Respir J 20 2 (2002) 339-343
8. Watanabe H. Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 71 5 (2002) 398-402
9. Muller C., Furst H., Reichenspurner H., Briegel J., Groh J., and Reichart B. Lung procurement by low-potassium dextran and the effect on preservation injury. Munich Lung Transplant Group. Transplantation 68 8 (1999) 1139-1143
10. Struber M., Wilhelmi M., Harringer W., Niedermeyer J., Anssar M., Kunsebeck A., Schmitto J.D., and Haverich A. Flush perfusion with low potassium dextran solution improves early graft function in clinical lung transplantation. Eur J Cardiothorac Surg 19 2 (2001) 190-194
11. Sandera P., Hillinger S., Stammberger U., Schoedon G., Zalunardo M., Weder W., and Schmid R.A. 8-Br-cyclic GMP given during reperfusion improves post-transplant lung edema and free radical injury. J Heart Lung Transplant 19 2 (2000) 173-178
12. Korom S., Hillinger S., Cardell M., Zhai W., Tang Q., Dutly A., Leskosek B., and Weder W. Sildenafil extends survival and graft function in a large animal lung transplantation model. Eur J Cardiothorac Surg 29 3 (2006) 288-293
13. Fiser S.M., Cope J.T., Kron I.L., Kaza A.K., Long S.M., Kern J.A., Tribble C.G., and Lowson S.M. Aerosolized prostacyclin (epoprostenol) as an alternative to inhaled nitric oxide for patients with reperfusion injury after lung transplantation. J Thorac Cardiovasc Surg 121 5 (2001) 981-982
14. Hillinger S. Survival and graft function in a large animal lung transplant model after 30 h preservation and substitution of the nitric oxide pathway. Eur J Cardiothorac Surg 20 3 (2001) 508-513
15. Kusano K.F., Date H., Fujio H., Miyaji K., Matsubara H., Nagahiro I., Satoh T., Shimizu N., and Ohe T. Recovery of cardiac function after living-donor lung transplantation in a patient with primary pulmonary hypertension. Circ J 66 3 (2002) 294-296
16. Olschewski H., Ghofrani H.A., Schmehl T., Winkler J., Wilkens H., Hoper M.M., Behr J., Kleber F.X., and Seeger W. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 132 6 (2000) 435-443
17. Sugiyama A., Satoh Y., Shiina H., Takahara A., Yoneyama M., and Hashimoto K. Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. J Cardiovasc Pharmacol 38 6 (2001) 940-946
18. Zhao L. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104 4 (2001) 424-428